Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

ER positive + PGR positive

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

ER positive + PGR positive	HER2 Negative Breast Cancer	ER positive + PGR positive	HER2 Negative Breast Cancer	anastrozole Sensitive: A2 - Guideline anastrozole Sensitive : A2	anastrozole Sensitive: A2 - Guideline anastrozole Sensitive : A2
ER positive + PGR positive	HER2 Positive Breast Cancer	ER positive + PGR positive	HER2 Positive Breast Cancer	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B
ER positive + PGR positive	HER2 Negative Breast Cancer	ER positive + PGR positive	HER2 Negative Breast Cancer	fulvestrant Sensitive: C2 – Inclusion Criteria fulvestrant Sensitive : C2	fulvestrant Sensitive: C2 – Inclusion Criteria fulvestrant Sensitive : C2
ER positive + PGR positive	HER2 Positive Breast Cancer	ER positive + PGR positive	HER2 Positive Breast Cancer	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
ER positive + PGR positive	HER2 Negative Breast Cancer	ER positive + PGR positive	HER2 Negative Breast Cancer	exemestane Sensitive: C3 – Early Trials exemestane Sensitive : C3	exemestane Sensitive: C3 – Early Trials exemestane Sensitive : C3
ER positive + PGR positive	HER2 Negative Breast Cancer	ER positive + PGR positive	HER2 Negative Breast Cancer	letrozole Sensitive: C3 – Early Trials letrozole Sensitive : C3	letrozole Sensitive: C3 – Early Trials letrozole Sensitive : C3
ER positive + PGR positive	HER2 Negative Breast Cancer	ER positive + PGR positive	HER2 Negative Breast Cancer	tamoxifen Sensitive: C3 – Early Trials tamoxifen Sensitive : C3	tamoxifen Sensitive: C3 – Early Trials tamoxifen Sensitive : C3
ER positive + PGR positive	Uterine Cancer	ER positive + PGR positive	Uterine Cancer	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3
ER positive + PGR positive	Uterine Leiomyosarcoma	ER positive + PGR positive	Uterine Leiomyosarcoma	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3
ER positive + PGR positive	HER2 Negative Breast Cancer	ER positive + PGR positive	HER2 Negative Breast Cancer	Aromatase inhibitor Sensitive: C3 – Early Trials Aromatase inhibitor Sensitive : C3	Aromatase inhibitor Sensitive: C3 – Early Trials Aromatase inhibitor Sensitive : C3
ER positive + PGR positive	Neuroendocrine Tumor	ER positive + PGR positive	Neuroendocrine Tumor	tamoxifen Sensitive: C3 – Early Trials tamoxifen Sensitive : C3	tamoxifen Sensitive: C3 – Early Trials tamoxifen Sensitive : C3
ER positive + PGR positive	HER2 Positive Breast Cancer	ER positive + PGR positive	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: C4 – Case Studies trastuzumab + pertuzumab Sensitive : C4	trastuzumab + pertuzumab Sensitive: C4 – Case Studies trastuzumab + pertuzumab Sensitive : C4